Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors

Drougas, James G.; Anthony, Lowell; Blair, Taylor K.; Lopez, Rigoberto; Wright, J. Kelly; Chapman, William C.; Webb, L.E.; Mazer, Murray J.; Meranze, Steven G.; Pinson, C. Wright

doi:10.1016/s0002-9610(98)00042-7

Cited by 113 publications

(29 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Transcatheter arterial chemoembolization (TACE), which consists of delivering a mixture of ethiodized oil, chemotherapeutic agents and embolic particles directly to the tumor, is commonly performed to treat these types of liver cancer. TACE is particularly effective in providing symptomatic relief and prolonging the life of patients with neuroendocrine tumors, especially those of the carcinoid type [4]. In addition, multiple studies, through neither randomized nor prospective, have shown TACE to have a survival benefit in patients with hepatocellular carcinoma when compared to historical data [5][6][7][8][9][10][11].…”

mentioning

confidence: 99%

Transcatheter Arterial Chemoembolization of Liver Tumors: Effects of Embolization Protocol on Injectable Volume of Chemotherapy and Subsequent Arterial Patency

Geschwind

Ramsey

Cleffken

et al. 2003

CardioVascular and Interventional Radiology

View full text Add to dashboard Cite

The purpose of this study was to determine whether transcatheter arterial chemoembolization (TACE) protocol affects the total volume of chemotherapy injected into the liver as well as subsequent arterial patency. A total of 160 patients with primary or secondary liver cancer were treated with 3 different chemoembolization protocols at a single institution. Data were analyzed retrospectively. Group 1 (n ϭ 36) consisted of slurry of chemotherapy, oil and polyvinyl alcohol particles (PVA), group 2 (n ϭ 91), chemotherapy and oil followed by PVA, and group 3 (n ϭ 33), chemotherapy and oil followed by Gelfoam pledgets. The total volume of chemotherapy injected into the liver was recorded. Arterial patency was determined during subsequent chemoembolizations. The mean percentage of total intended chemotherapy dose administered was 54.6% for group 1, 75.3% for group 2, and 80.6% for group 3. Arterial patency at follow-up angiography was 56% for group 1, 74% for group 2, and 81% for group 3. The slurry protocol (group 1) significantly reduced arterial patency and injectable volume of chemotherapy during TACE.

show abstract

mentioning

confidence: 99%

Transcatheter Arterial Chemoembolization of Liver Tumors: Effects of Embolization Protocol on Injectable Volume of Chemotherapy and Subsequent Arterial Patency

Geschwind

Ramsey

Cleffken

et al. 2003

CardioVascular and Interventional Radiology

View full text Add to dashboard Cite

show abstract

“…Obliterating agents include polyvinyl chloride and gel-foam powder. It appears that ischaemia may increase the sensitivity to chemotherapeutic agents, hence the rationale behind transarterial chemoembolisation utilising concomitant DOX or cisplatin (Drougas et al 1998). Contraindications to embolisation include complete portal vein obstruction, hepatic insufficiency, biliary reconstruction and severe carcinoid heart disease.…”

Section: Embolisation and Ablative Methodsmentioning

confidence: 99%

Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours

Khan

Caplin²

2011

Endocrine-Related Cancer

View full text Add to dashboard Cite

Patients with neuroendocrine tumours (NETs) are best managed in a specialist centre as part of a multidisciplinary team comprising gastroenterologists, oncologists, endocrinologists, gastrointestinal and hepatopancreaticobiliary surgeons, pathologists, nuclear medicine physicians and technicians, radiologists, specialist nurses, pharmacists, biochemists and dieticians. This should ideally be led by a clinician with experience and interest in NETs. Although the number of medical treatments and clinical trials has increased in the decade, there is still a lack of prospective randomised trials; thus, management is mainly based on limited often single-centre studies, although there are now formal guidelines based on consensus expert opinion. We have outlined the current optimal management of patients with NETs. We have reviewed therapeutic options including surgery, somatostatin analogues and other biotherapies and peptide receptor-targeted therapy. We have discussed the challenge in managing hepatic metastases including hepatic artery embolisation, ablation and orthotopic liver transplant. In addition, we have briefly reviewed the emerging therapies such as the mammalian target of rapamycin and angiogenic inhibitors and the newer somatostatin analogues.

show abstract

“…For chemoembolization, an emulsion of a cytotoxic drug such as doxorubicin (50 mg/m 2 ) or streptozocin (1.5 g/m 2 ) is used until complete stasis of flow. Individual embolizations are spaced 4 weeks apart and the majority of patients complete their embolizations in 2 or 3 stages [34,35].…”

Section: Hepatic Artery Embolizationmentioning

confidence: 99%

Management of Gastro-intestinal Neuroendocrine Tumors with Liver Metastases: A Comprehensive Review

Kanti¹

2012

TOCOLCJ

View full text Add to dashboard Cite

Neuroendocrine tumors have been studied for over a century and several advances have been made in understanding of the pathophysiology, diagnostic methods, management, and underlying genetics. Advances in pathology and identification of serum markers have helped to identify subsets of tumors. Diagnostic modalities like somatostatin receptor scintigraphy (SRS) with CT fusion imaging, Endoscopic ultrasonography (EUS), PET scan and MRI have vastly improved the diagnosis of these tumors. The management of these tumors requires a multidisciplinary approach including endocrinology, interventional radiology, medical surgery, and medical & radiation oncology. The aggressive use of curative and cytoreductive surgery, orthotopic liver transplantation as well as interventional radiological techniques including embolization, chemo-embolization, and radiofrequency ablation in conjunction with judicial use of somatostatin analogues for symptom control has become the frontline of treatment. For the vast majority of patients with unresectable metastatic disease, older chemotherapeutic agents have shown disappointing results, yet new regimens and new classes of drugs hold great promise.Clinicians need to be aware with the disease pattern, natural history and disease progression, which are characteristic of these tumors. A multidisciplinary approach is the evidence based logical approach to treat these diseases.

show abstract

Hepatic artery chemoembolization for management of patients with advanced metastatic carcinoid tumors

Cited by 113 publications

References 19 publications

Transcatheter Arterial Chemoembolization of Liver Tumors: Effects of Embolization Protocol on Injectable Volume of Chemotherapy and Subsequent Arterial Patency

Transcatheter Arterial Chemoembolization of Liver Tumors: Effects of Embolization Protocol on Injectable Volume of Chemotherapy and Subsequent Arterial Patency

Therapeutic management of patients with gastroenteropancreatic neuroendocrine tumours

Management of Gastro-intestinal Neuroendocrine Tumors with Liver Metastases: A Comprehensive Review

Contact Info

Product

Resources

About